Overview

• P3 Health Q3 revenue falls 5% yr/yr due to network rationalization

• Adjusted EBITDA loss for Q3 was $45.9 mln

• Company aims for $120-$170 mln EBITDA expansion, targeting profitability by 2026

Outlook

• P3 Health Partners expects 2025 revenue between $1.4 bln and $1.45 bln

• Company anticipates 2025 medical margin of $67 mln to $82 mln

• P3 projects 2025 adjusted EBITDA loss of $110 mln to $95 mln

Result Drivers

• CARE ENABLEMENT MODEL - Expansion of Care Enablement Model drove positive momentum in core business, per CEO Aric Coffman

• NETWORK RATIONALIZATION - Revenue decline attributed to intentional reduction in membership due to network and payer rationalization

• STABLE MEDICAL COSTS - Medical cost trends remained stable, normalized for prior-year adjustments

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for P3 Health Partners Inc is $13.00, about 46.2% above its November 13 closing price of $7.00

Press Release: ID:nBw40lvbwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)